Kevin P. Starr, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 52,631 shares at $23.41 ($1.2M) on 2013-03-26, disclosed to the SEC on 2013-03-26.
Scheduled sale ($1.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.56 | 26,631 | $627K | 50.8% |
| 2 | $23.41 | 26,000 | $609K | 49.2% |
| Total | $23.49 avg | 52,631 | $1.2M | 100% |
| Filing → |
| FULC | BUY | 2019-07-22 | $1.3M | — | Filing → |
| SAGE | SELL | 2018-04-19 | $10.0M | — | Filing → |
| MYOK | SELL | 2018-01-05 | $34.3M | — | Filing → |